nach oben

Digestive Diseases and Sciences

Erschienen in:

01.03.2010 | Original Article

Comparison of the Effect of Azithromycin Versus Erythromycin on Antroduodenal Pressure Profiles of Patients with Chronic Functional Gastrointestinal Pain and Gastroparesis

verfasst von: Baharak Moshiree, Renee McDonald, Wei Hou, Phillip P. Toskes

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Current pharmacologic treatments for gastroparesis have been disappointing due to the limited options available. Erythromycin ethylsuccinate is a potent prokinetic agent that stimulates gastric emptying. Recently, erythromycin has been linked to the occurrences of sudden cardiac death due to QT prolongation. Azithromycin is similar to erythromycin in structure but does not have significant drug–drug interactions as seen with erythromycin.

Purpose

This study aims to determine whether azithromycin stimulates antral activity in patients with chronic gastrointestinal pain and refractory gastroparesis.

Methods

Small bowel manometric data on 30 patients undergoing clinical evaluation for chronic digestive problems or documented refractory gastroparesis were reviewed. Antral activity was measured after infusion of erythromycin 250 mg intravenous and azithromycin (500 or 250 mg intravenous) given at different intervals during the small bowel manometry. The parameters measured included the total duration of effect, mean amplitude of antral contractions, duration of the highest antral contraction phase, number of cycles per minute, and the motility index.

Results

Comparison of erythromycin and azithromycin at similar doses showed a similar positive effect on antral activity. However, comparison of erythromycin and azithromycin at the higher dose of 500 mg showed that the mean amplitude, duration of antral activity, and motility index were significantly increased with azithromycin (P < 0.05).

Conclusions

Azithromycin stimulates antral activity similar to erythromycin and moreover has a longer duration of effect. However, unlike erythromycin, azithromycin does not have significant drug–drug interactions and may be a potential new medication for the treatment of gastroparesis and gastrointestinal dysmotility.

Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398–2404.CrossRefPubMed

Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America. Prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci. 2000;45:809–818.CrossRefPubMed

Talley NJ, Locke GR, Lahr BD, et al. Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut. 2006;55:933–939.CrossRefPubMed

Joshi P, Toskes PP. Clinical approach to chronic pancreatitis. J Clin Outcomes Manage. 2005;12(8):419–428.

Malagelada Jr, Stanghellini V. Manometric evaluation of functional upper gut symptoms. Gastroentererology. 1985;88(5 Pt 1):1223–1231.

Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology. 1986;91:94–99.PubMed

Jones KL, Berry M, Kong MF, Kwiatek MA, Samson M, Horowitz M. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care. 1999;22(2):339–344.CrossRefPubMed

Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med. 1990;322:1028–1031.PubMed

Hasler WL, Heldsinger A, Chung OY. Erythromycin contracts rabbit colon myocytes via occupation of motilin receptors. Am J Physiol. 1992;262(1 Pt 1):G50–G55.PubMed

10.

Tack J, Janssens J, Vantrappen G, et al. Effect of erythromycin on gastric motility in controls and diabetic gastroparesis. Gastroenterology. 1992;103(1):72–79.PubMed

11.

Sarna SK, Soergel KH, Koch TR, et al. Gastrointestinal motor effects of erythromycin in humans. Gastroenterology. 1991;101:1488–1496.PubMed

12.

Otterson MF, Sarna SK. Gastrointestinal motor effects of erythromycin. Am J Physiol. 1990;259:G355–G363.PubMed

13.

Tomomasa T, Karoumi T, Arai H, Wakabayashi K, Itoh Z. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci. 1986;31:157–161.CrossRefPubMed

14.

Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal tract activity in the dog. Am J Physiol. 1984;247:G688–G694.PubMed

15.

Annese V, Janssens J, Vantrappen G, et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology. 1992;102:823–828.PubMed

16.

Strum A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion. 1999;60:422–427.CrossRef

17.

Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089–1096.CrossRefPubMed

18.

Wisialowski T, Crimin K, Engtrakul J, O’Donnell J, Fermini B, Fossa AA. Differentiation of the antibacterials moxifloxacin, erythromycin and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther. 2006;318(1):352–359.CrossRefPubMed

19.

Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof, Fabritz L, Breithardt G, Haverkamp W. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002; 303(1): 218–225.

20.

Hopkins S. Clinical toleration and safety of azithromycin. Am J Med. 1991;91(3A):40S–45S.CrossRefPubMed

21.

Sifrim D, Matsuo H, Janssens J, Vantrappen G. Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. Drugs Exp Clin Res. 1994;20(3):121–126.PubMed

22.

Florescu DF, Murphy PJ, Kalil AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther. 2009 Mar 27 [Epub ahead of print].

23.

Sutera L, Dominguez LJ, Belvedere M, et al. Azithromycin in an older woman with diabetic gastroparesis. Am J Ther. 2008;15(1):85–88.CrossRefPubMed

24.

Parkman HP, Trate DM, Knight LC, Brown KL, Maurer AH, Fisher RS. Cholinergic effects on human gastric motility. Gut. 1999;45:346–354.PubMedCrossRef

25.

Camilleri M, Malagelada JR, Brown ML, Becker G, Zinsmeister AR. Relation between antral motility and gastric emptying of solids and liquids in humans. Am J Physiol. 1985;249(5.1):G580–G585.PubMed

26.

Camilleri M, Malagelada JR. Abnormal intestinal motility in diabetics with gastroparesis syndrome. Eur J Clin Invest. 1984;14(6):420–427.CrossRefPubMed

27.

Thumshirn M, Bruninga K, Camilleri M. Simplifying the evaluation of postprandial antral motor function in patients with suspected gastroparesis. Am J Gastroenterol. 1997;92(9):1496–1500.PubMed

28.

Borotolotti M, Annese V, Coccia G. Twenty-four hour ambulatory antroduodenal manometry in normal subjects (co-operative study). Neurogastroenterol Motil. 2000;12:231–238.CrossRef

29.

Code CF, Marlett JA. The interdigestive myo-electric complex of the stomach and small bowel of dogs. J Physiol. 1975;246(2):289–309.PubMed

30.

Holland R, Gallagher MD, Quigly EM. An evaluation of an ambulatory manometry system in assessment of antroduodenal motor activity. Dig Dis Sci. 1996;41:1531–1537.CrossRefPubMed

31.

Malagelada JR, Rees WD, Mazzotta LJ, Go VL. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide and bethanechol. Gastroenterology. 1980;78(2):286–293.PubMed

32.

Devasia RA, Jones TF, Collier B, Schaffner W. Compliance with azithromycin versus erythromycin in the setting of a pertussis outbreak. Am J Med Sci. 2009;337(3):176–178.CrossRefPubMed

33.

Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol. 2007;30(12):1579–1582.PubMed

34.

Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other precipitating factors. J Interv Card Electrophysiol. 2007;18(3):243–246.CrossRefPubMed

35.

Grayston JT, Kronmal RA, Jackson LA, et al. ACES investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352(16):1637–1645.CrossRefPubMed

36.

Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents. 2001;18(suppl 1):S71–S76.CrossRefPubMed

37.

Bologna SD, Hasler WL, Owyang C. Down-regulation of motilin receptors on rabbit colon myocytes by chronic oral erythromycin. J Pharmacol Exp Ther. 1993;226(2):852–856.

38.

Depoortere I, Peeters TL, Vantrappen G. Effect of erythromycin and of octreotide on motilin receptor density in the rabbit. Regul Pept. 1991;32(2):85–94.CrossRefPubMed

39.

Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with, without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2000;14(12):1653–1661.CrossRefPubMed

40.

Depoortere I, Peeters TL, Matthijs G, Cachet T, Hoogmartens J, Vantrappen G. Structure-activity relation of erythromycin related macrolides in inducing contractions and displacing bound motilin in rabbit duodenum. J Gastrointest Motil. 1989;1:150–159.

Titel: Comparison of the Effect of Azithromycin Versus Erythromycin on Antroduodenal Pressure Profiles of Patients with Chronic Functional Gastrointestinal Pain and Gastroparesis
verfasst von: Baharak Moshiree
Renee McDonald
Wei Hou
Phillip P. Toskes
Publikationsdatum: 01.03.2010
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 3/2010
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-009-1038-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Comparison of the Effect of Azithromycin Versus Erythromycin on Antroduodenal Pressure Profiles of Patients with Chronic Functional Gastrointestinal Pain and Gastroparesis

Abstract

Background

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Long-Term Impact of Capsule Endoscopy in Patients Referred for Iron-Deficiency Anemia

Effective Endoscope for Endoscopic Retrograde Cholangiopancreatography in Patients with Roux-en-Y Anastomosis: A Single-, Double-, or “Short” Double-Balloon Enteroscope?

Biliary Sphincter of Oddi Dysfunction Type I Versus Occult Biliary Microlithiasis in Post-cholecystectomy Patients: Are They Both Part of the Same Clinical Entity?

Surveillance for Hepatocellular Carcinoma Improves Survival in Asian-American Patients with Hepatitis B: Results from a Community-Based Clinic

The Societal Burden of HBV-Related Disease: South Korea

The Clinical Value of Serum Connective Tissue Growth Factor in the Assessment of Liver Fibrosis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin